Targeted Oncology10d
LYT-200 Gains FDA Fast Track Status in Acute Myeloid Leukemia
LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...
Yahoo Finance16d
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatment LYT-200 is ...
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
LYT-200 is currently being evaluated in two Phase 1/2 trials for the potential treatment of AML/MDS and head and neck cancers PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company” ...
PureTech announces receipt of FDA Fast Track Designation for LYT-200 in AML
PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class ...
Yahoo Finance15d
PureTech announces receipt of FDA Fast Track Designation for LYT-200 in AML
The FDA has also granted orphan drug designation to LYT-200 for the treatment of AML as well as a separate Fast Track designation for the treatment of recurrent/metastatic head and neck squamous ...
Business Insider16d
PureTech Says FDA Grants Fast Track Designation For LYT-200 In Acute Myeloid Leukemia
(RTTNews) - Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LYT-200, a first-in-class ...